The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19. Participants will take PF-07817883 by mouth up to 2 times a day. This study may also evaluate how much PF-07817883 gets into the body when taken as pill. We may study if people's diets can affect this study medicine. We may also examine how PF-07817883 is processed and removed by the human body. Finally, we may look into if PF-07817883 has potential to interact with midazolam.
14 Primary · 84 Secondary · Reporting Duration: Day 10 Pre-dose (0 hours) to 12 hours
90 Total Participants · 22 Treatment Groups
Primary Treatment: PF-07817883 Dose 4 in PART-1 · Has Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 60 · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: